½ÃÀ庸°í¼­
»óǰÄÚµå
1336645

ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀå - Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº° ¹× ¿¹Ãø(2023-2032³â)

Automated Immunoassay Analyzers Market - By Product (Immunofluorescence, Chemiluminescence, ELISA), By Application (Infectious Diseases, Endocrinology, Allergy Testing), By End-use (Hospitals, Diagnostic Laboratories), & Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 210 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ¼¼°è ½ÃÀåÀº 2023³âºÎÅÍ 2032³â±îÁö Å« ÆøÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸¸¼º Áúȯ°ú °¨¿°¼º ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, WHO¿¡ µû¸£¸é 2021³â¿¡´Â °áÇÙÀÌ ¾à 1,060¸¸ ¸íÀÇ °Ç°­¿¡ ¿µÇâÀ» ¹ÌÄ¡°í, 2¾ï 4,700¸¸ ¸íÀÌ ¸»¶ó¸®¾Æ¿¡ °¨¿°µÉ °ÍÀ̸ç, 2022³â ¸»¿¡´Â ¾à 3,900¸¸ ¸íÀÌ HIV¿¡ °¨¿°µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÖ½À´Ï´Ù.

ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â´Â ´ë·®ÀÇ »ùÇÃÀ» ó¸®ÇÒ ¼ö ÀÖ´Â ³ôÀº 󸮷®°ú È¿À²¼ºÀ» Á¦°øÇÏ¿© Áø´Ü °Ë»ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. Áö¼ÓÀûÀÎ ±â¼ú ¹ßÀüÀ¸·Î Á¤È®µµ¿Í ¹Î°¨µµ°¡ Çâ»óµÈ ÀÚµ¿È­ ½Ã½ºÅÛÀÌ °³¹ßµÇ¾î ȯÀÚ °á°ú¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áúº´ÀÇ Á¶±â ¹ß°ß°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÓ»ó ½ÇÇè½Ç°ú ¿¬±¸ ½Ã¼³¿¡¼­ ÀÌ·¯ÇÑ ºÐ¼® ÀåºñÀÇ Ã¤ÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸é¿ª ºÐ¼® °Ë»çÀÇ ÀÚµ¿È­´Â ÀÎÀû ¿À·ùÀÇ À§ÇèÀ» ÁÙÀÌ°í °Ë»ç½ÇÀÇ »ý»ê¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀå¿¡ ´õ¿í ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Àüü ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç°º°·Î´Â ELISA(È¿¼Ò °áÇÕ ¸é¿ª ÈíÂø ºÐ¼®¹ý) ºÐ¾ß°¡ 2023-2032³â Å« ¼öÀÍÀ» âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ELISA´Â Ç׿ø ¹× Ç×ü¸¦ Æ÷ÇÔÇÑ ´Ù¾çÇÑ ºÐ¼®¹°ÁúÀ» °ËÃâÇÏ´Â µ¥ ÀÖ¾î ³ôÀº ¹Î°¨µµ¿Í ƯÀ̼ºÀ» Á¦°øÇÏ´Â ³Î¸® »ç¿ëµÇ´Â ´Ù¸ñÀû ¸é¿ª ÃøÁ¤ ±â¼úÀÔ´Ï´Ù. ÇコÄÉ¾î ¾÷°è¿¡¼­´Â Áúº´ÀÇ Á¶±â Áø´Ü°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ELISA ±â´ÉÀ» °®Ãá ÀÚµ¿ ¸é¿ª ÃøÁ¤ ºÐ¼® Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â ¾à¹° ¸ð´ÏÅ͸µ ºÐ¾ß°¡ 2023-2032³â ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÚµ¿ ¸é¿ª ÃøÁ¤ Àåºñ´Â ȯÀÚ »ùÇÃÀÇ ¾à¹° ³óµµ¸¦ È¿À²ÀûÀ̰í Á¤È®ÇÏ°Ô ÃøÁ¤ÇÒ ¼ö Àֱ⠶§¹®¿¡ ¾à¹° ¸ð´ÏÅ͸µ¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ±â´ÉÀº Ä¡·á¾à¹° ¸ð´ÏÅ͸µ¿¡ ÇʼöÀûÀ̸ç, ÃÖÀûÀÇ ¾à¹° Åõ¿©¿Í ȯÀÚÀÇ ¾ÈÀüÀ» º¸ÀåÇÕ´Ï´Ù. ¶ÇÇÑ, °³º°È­ ÀÇ·á°¡ ÁÖ¸ñ¹ÞÀ¸¸é¼­ ¾à¹° ¸ð´ÏÅ͸µÀº ȯÀÚ °³°³Àο¡ ¸Â´Â Ä¡·á ¿ä¹ýÀ» Á¶Á¤ÇÏ´Â µ¥ ÀÖ¾î ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

ÃÖÁ¾ ¿ëµµÀÇ °æ¿ì, 2023³âºÎÅÍ 2032³â±îÁö ¿¬±¸ ±â°ü ¹× Çмú ¿¬±¸¼Ò ºÐ¾ß°¡ ½ÃÀå¿¡ Å« ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®±â´Â ³ôÀº 󸮷®°ú Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇÏ¿© ´Ù¾çÇÑ ¸é¿ª ÃøÁ¤ ½ÇÇèÀ» ¼öÇàÇÏ´Â µ¥ À¯¿ëÇÑ µµ±¸°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. »ýÀÇÇÐ ¿¬±¸¿Í ½Å¾à°³¹ß¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â´Â ½ÇÇè½Ç ¿öÅ©Ç÷ο츦 °£¼ÒÈ­ÇÏ°í µ¥ÀÌÅÍ Ç°ÁúÀ» Çâ»ó½ÃÄÑ ¿¬±¸ ÁøÇàÀ» °¡¼ÓÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »ç¿ëÀÚ Ä£È­ÀûÀÎ ±â´É°ú °í±Þ ±â´ÉÀ¸·Î ¼÷·Ã µÈ ¿¬±¸ÀÚ ¹× Çлý ¸ðµÎ¿¡°Ô ÀûÇÕÇÏ¿© º¸±ÞÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº°·Î º¸¸é À¯·´ÀÇ ÀÚµ¿ ¸é¿ªÃøÁ¤ ±â±â ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È ÇコÄɾî ÀÎÇÁ¶óÀÇ ¹ßÀü°ú ÀÇ·áºñ ÁöÃâ Áõ°¡·Î ÀÎÇØ À¯·´¿¡¼­ °ßÀηÂÀ» ¹ßÈÖÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼® Àåºñ´Â ´Ù¾çÇÑ ºÐ¼® ´ë»óÀ» ¹Î°¨ÇÏ°í Æ¯ÀÌÀûÀ¸·Î °ËÃâÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÓ»ó ½ÇÇè½Ç°ú ¿¬±¸ ½Ã¼³¿¡¼­ ±ÍÁßÇÑ ÀÚ»êÀ¸·Î Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯·´¿¡¼­´Â Áúº´ÀÇ Á¶±â ¹ß°ß°ú °³ÀÎ ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ÀÚµ¿ ¸é¿ª ÃøÁ¤ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. È¿À²ÀûÀ̰í Á¤È®ÇÑ Áø´ÜÀÌ À¯·´¿¡¼­ Áö¼ÓÀûÀ¸·Î ¿ì¼±¼øÀ§¸¦ Â÷ÁöÇÔ¿¡ µû¶ó ÀÚµ¿ ¸é¿ª ÃøÁ¤±â ½ÃÀåÀº À¯·´¿¡¼­ Áö¼ÓÀûÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

  • »ê¾÷ Ä¿¹ö¸®Áö
  • ½ÃÀå ¹üÀ§¿Í Á¤ÀÇ
  • ±âº» ÃßÁ¤°ú ÀÛ¾÷
    • µ¥ÀÌÅÍ ¼öÁý
  • ¿¹Ãø ÆÄ¶ó¹ÌÅÍ
  • ¼¼°è ·¹º§¿¡¼­ÀÇ COVID-19ÀÇ ¿µÇâ
  • µ¥ÀÌÅÍ °ËÁõ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ µ¥ÀÌÅÍ
    • 2Â÷
      • À¯·á Á¤º¸ Ãâó
      • ¹«º¸¼ö Á¤º¸ Ãâó

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â »ê¾÷ ÀλçÀÌÆ®

  • »ýÅÂ°è ºÐ¼®
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ÷´Ü Á¦Ç°ÀÇ ²÷ÀÓ¾ø´Â µµÀÔ
      • ½ÇÇè½Ç ÀÚµ¿È­ Ãß¼¼ »ó½Â
      • °¨¿°Áõ Áõ°¡
      • ¸é¿ªÃøÁ¤ ºÐ¼®±â ÀÓ»ó ÀÀ¿ë È®´ë
    • ¾÷°èÀÇ ÀáÀçÀû À§Çè°ú °úÁ¦
      • ÀÚ°ÝÀ» °®Ãá ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·
  • ¼ºÀå °¡´É¼º ºÐ¼®
    • Á¦Ç°º°
    • ¿ëµµº°
    • ÃÖÁ¾ ¿ëµµº°
  • COVID-19 ¿µÇ⠺м®
  • ±ÔÁ¦ »óȲ
    • ¹Ì±¹
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ÇâÈÄ ½ÃÀå µ¿Çâ
  • ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â Á¦Ç° °³¿ä
  • ±â¼ú Àü¸Á
  • ¼¼ÆÃº°, ¿ëµµº° ¼¼°è ½ÃÀå Á¡À¯À² ºÐ¼®
  • °ÝÂ÷ ºÐ¼®
  • Porters ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï »óȲ

  • ¼­·Ð
  • ±â¾÷ ¸ÅÆ®¸¯½º ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • ±â¾÷ Á¡À¯À² ºÐ¼®
    • ¼¼°è
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • MEA
  • º¥´õ ¸ÅÆ®¸¯½º ºÐ¼®
  • 2022³â Àü·« ´ë½Ãº¸µå

Á¦5Àå ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Ç°º°

  • ÁÖ¿ä µ¿Çâ
  • ¸é¿ªÇü±¤
  • È­Çй߱¤
  • ELISA(È¿¼Ò °áÇÕ ¸é¿ªÈíÂø ÃøÁ¤¹ý)
  • È¿¼Ò °áÇÕ Çü±¤ ½Ã½ºÅÛ
  • ¸ÖƼÇ÷º½º ¾î¼¼ÀÌ ½Ã½ºÅÛ
  • ¹æ»ç¸é¿ªÃøÁ¤¹ý

Á¦6Àå ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ
  • °¨¿°Áõ
    • ÀÎÇ÷翣ÀÚ
    • HIV
    • CÇü °£¿°
    • ¼º°¨¿°Áõ(STD)
    • ÇコÄÉ¾î °ü·Ã °¨¿°(HAI)
    • È£Èí±â °¨¿°Áõ
    • ¿­´ëº´
    • ±âŸ
  • ³»ºÐºñÇÐ
  • ¾àÁ¦ ¸ð´ÏÅ͸µ
  • ½ÉÀ庴ÇÐ
  • Á¾¾çÇÐ
  • ¾Ë·¹¸£±â °Ë»ç
  • ±âŸ

Á¦7Àå ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä µ¿Çâ
  • º´¿ø
  • Áø´Ü ¿¬±¸¼Ò
  • ¿¬±¸¡¤Çмú ¿¬±¸¼Ò
  • Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±âŸ

Á¦8Àå ÀÚµ¿ ¸é¿ªÃøÁ¤ ºÐ¼®±â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä µ¿Çâ
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • Æú¶õµå
    • ½º¿þµ§
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • Àεµ³×½Ã¾Æ
    • Çʸ®ÇÉ
    • º£Æ®³²
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • Ä¥·¹
    • Æä·ç
  • MEA
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • ÅÍŰ
    • À̽º¶ó¿¤
    • À̶õ

Á¦9Àå ±â¾÷ °³¿ä

  • Abbott Laboratories
  • BioMerieux
  • F. Hoffmann-La Roche AG
  • Becton Dickinson and Company
  • Biokit
  • Carolina Liquid Chemistries Corporation
  • Inova DX
  • Luminex Corporation
  • Meril Life Sciences
  • Ortho Clinical Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • BioRad Laboratories
  • Aesku Diagnotics
  • Arlington Scientific
  • Perkin Elmer
  • Diasorin
ksm 23.09.15

Global Automated Immunoassay Analyzers Market will garner significant growth between 2023 and 2032. The increasing prevalence of chronic and infectious diseases has created a higher demand for rapid and accurate diagnostic solutions. According to WHO, Tuberculosis impacted the health of an estimated 10.6 million individuals in 2021, 247 million people had malaria infection, and an estimated 39 million people were suffering from HIV at the end of 2022.

Automated immunoassay analyzers offer high throughput and efficiency in processing large volumes of samples, meeting the rising demand for diagnostic testing. Consistent technological upgrades have led to the development of automated systems with enhanced accuracy and sensitivity, improving patient outcomes. Furthermore, the growing focus on early disease detection and personalized medicine is driving the adoption of these analyzers in clinical laboratories and research facilities. The automation of immunoassay testing reduces the risk of human error and enhances laboratory productivity, further contributing to market growth.

The overall Automated Immunoassay Analyzers Market is classified based on product, application, end-user, and region.

Based on product, the ELISA (enzyme-linked immunosorbent assay) segment will amass sizeable revenue over 2023-2032. ELISA is a widely used and versatile immunoassay technique, offering high sensitivity and specificity in detecting various analytes, including antigens and antibodies. As the healthcare industry emphasizes early disease diagnosis and personalized medicine, the need for automated immunoassay analyzers with ELISA capabilities is increasing.

By application, the drug monitoring segment will show a high growth rate from 2023-2032. Automated immunoassay analyzers play a crucial role in drug monitoring, enabling efficient and precise measurement of drug levels in patient samples. This capability is essential for therapeutic drug monitoring, ensuring optimal drug dosing and patient safety. Moreover, as personalized medicine gains prominence, drug monitoring becomes even more critical in tailoring treatment regimens to individual patients.

Regarding the end-user, the research and academic laboratories segment will contribute significantly to the market from 2023-2032. These analyzers offer high-throughput capabilities and accurate results, making them invaluable tools for conducting various immunoassay experiments. With the increasing focus on biomedical research and drug discovery, automated immunoassay analyzers streamline laboratory workflows, improve data quality, and accelerate research progress. Additionally, their user-friendly features and advanced functionalities make them suitable for both experienced researchers and students, further driving their adoption.

Regionally, the Europe automated immunoassay analyzers market will gain traction during the forecast period due to the region's well-established healthcare infrastructure and rising healthcare expenditure. These analyzers offer high sensitivity and specificity in detecting a wide range of analytes, making them valuable assets in clinical laboratories and research facilities. Moreover, Europe's focus on early disease detection and personalized medicine further contributes to the demand for automated immunoassay analyzers. As the region continues to prioritize efficient and accurate diagnostics, the market for automated immunoassay analyzers is poised for continued growth in Europe.

Table of Contents

Chapter 1 Methodology

  • 1.1 Industry coverage
  • 1.2 Market scope & definitions
  • 1.3 Base estimates & working
    • 1.3.1 Data collection
  • 1.4 Forecast parameters
  • 1.5 COVID-19 impact at global level
  • 1.6 Data validation
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Automated immunoassay analyzers industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends
    • 2.1.2 Regional trends
    • 2.1.3 Product trends
    • 2.1.4 Application trends
    • 2.1.5 End-use trends

Chapter 3 Automated Immunoassay Analyzers Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Incessant introduction of advanced products
      • 3.2.1.2 Rising trend towards lab automation
      • 3.2.1.3 Increasing prevalence of infectious diseases
      • 3.2.1.4 Expanding clinical applications of immunoassay analyzers
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Dearth of qualified and trained professionals
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By application
    • 3.3.3 By end-use
  • 3.4 COVID-19 impact analysis
  • 3.5 Regulatory landscape
    • 3.5.1 U.S.
    • 3.5.2 Europe
    • 3.5.3 Asia Pacific
  • 3.6 Future market trends
  • 3.7 Automated immunoassay analyzers product outline
  • 3.8 Technology landscape
  • 3.9 Global market share analysis, by settings and application
  • 3.10 Gap analysis
  • 3.11 Porter's analysis
  • 3.12 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

  • 4.1 Introduction
  • 4.2 Company matrix analysis, 2022
  • 4.3 Competitive positioning matrix
  • 4.4 Company market share analysis, 2022
    • 4.4.1 Global
    • 4.4.2 North America
    • 4.4.3 Europe
    • 4.4.4 Asia Pacific
    • 4.4.5 Latin America
    • 4.4.6 MEA
  • 4.5 Vendor matrix analysis
  • 4.6 Strategy dashboard, 2022

Chapter 5 Automated Immunoassay Analyzers Market Size and Forecast, By Product (USD Million & Units)

  • 5.1 Key trends, product
  • 5.2 Immunofluorescence
  • 5.3 Chemiluminescence
  • 5.4 ELISA (enzyme-linked immunosorbent assay)
  • 5.5 Enzyme linked fluorescent system
  • 5.6 Multiplexed assay system
  • 5.7 Radioimmunoassay

Chapter 6 Automated Immunoassay Analyzers Market Size and Forecast, By Application (USD Million)

  • 6.1 Key trends, application
  • 6.2 Infectious disease
    • 6.2.1 Influenza
    • 6.2.2 HIV
    • 6.2.3 Hepatitis C
    • 6.2.4 Sexually Transmitted Disease (STD)
    • 6.2.5 Healthcare-Associated Infection (HAI)
    • 6.2.6 Respiratory infection
    • 6.2.7 Tropical disease
    • 6.2.8 Others
  • 6.3 Endocrinology
  • 6.4 Drug Monitoring
  • 6.5 Cardiology
  • 6.6 Oncology
  • 6.7 Allergy Testing
  • 6.8 Others

Chapter 7 Automated Immunoassay Analyzers Market Size and Forecast, By End-use (USD Million)

  • 7.1 Key trends, end-use
  • 7.2 Hospitals
  • 7.3 Diagnostic Laboratories
  • 7.4 Research and Academic Laboratories
  • 7.5 Pharmaceutical and Biotechnology Companies
  • 7.6 Others

Chapter 8 Automated Immunoassay Analyzers Market Size and Forecast, By Region (USD Million)

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Poland
    • 8.3.7 Sweden
    • 8.3.8 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Indonesia
    • 8.4.7 Philippines
    • 8.4.8 Vietnam
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Columbia
    • 8.5.5 Chile
    • 8.5.6 Peru
  • 8.6 MEA
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Turkey
    • 8.6.5 Israel
    • 8.6.6 Iran

Chapter 9 Company Profiles

  • 9.1 Abbott Laboratories
  • 9.2 BioMerieux
  • 9.3 F. Hoffmann-La Roche AG
  • 9.4 Becton Dickinson and Company
  • 9.5 Biokit
  • 9.6 Carolina Liquid Chemistries Corporation
  • 9.7 Inova DX
  • 9.8 Luminex Corporation
  • 9.9 Meril Life Sciences
  • 9.10 Ortho Clinical Diagnostics
  • 9.11 Randox Laboratories
  • 9.12 Siemens Healthcare
  • 9.13 BioRad Laboratories
  • 9.14 Aesku Diagnotics
  • 9.15 Arlington Scientific
  • 9.16 Perkin Elmer
  • 9.17 Diasorin
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦